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Ablation of macrophages 
halts progression of crescentic 
glomerulonephritis
Th e role of macrophages in the initiation and progression of 
glomerular diseases has been a subject of investigation and 
debate for 30 years. Duffi  eld et al. used an elegant transgenic 
approach to eliminate macrophages in a mouse model of 
progressive, crescentic glomerulonephritis (GN) in which 
macrophages were ablated by minute injections of diphtheria 
toxin for 15 and 20 days. Macrophage depletion reduced the 
number of glomerular crescents, improved renal function, and 
reduced proteinuria. Morphometric analysis of renal tubules 
and interstitium revealed a marked attenuation of tubular injury 
that was associated with decreased proliferation and apoptosis 
of tubular cells. Moreover, interstitial myofi broblasts and fi brosis 
were reduced. In the presence of macrophages, interstitial 
myofi broblasts exhibited increased levels of both proliferation 
and apoptosis. Th ese results suggest that macrophages support 
renal myofi broblasts in a high-turnover state and in matrix 
deposition and that macrophages are necessary for disease 
progression. Th us, the outcome of persistent macrophage 
infi ltration is progressive injury, loss of epithelial cells, and 
development of interstitial fi brosis. Th e elegant approach of 
macrophage depletion described here can now be used in other 
models of renal diseases to better defi ne the role of these cells in 
progressive renal damage. (Am J Pathol 2005; 167: 1207–1219)
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Randomized study of plasma 
exchange when myeloma presents 
as acute renal failure
Two previous small trials provided confl icting evidence 
about the benefi ts of plasma exchange for patients with acute 
renal failure at the onset of multiple myeloma. To further 
examine this question, Clark et al. carried out an open-label, 
randomized study stratifi ed by chemotherapy and dialysis 
dependence. It was conducted from 1998 to 2004 in the hospital 
plasma exchange units of 14 Canadian medical centers. Study 
participants included 104 patients between 18 and 81 years of 
age with acute renal failure at the onset of myeloma. Th ey were 
randomly assigned to conventional therapy plus fi ve to seven 
plasma exchanges of 50 ml per kg of body weight of 5% human 
serum albumin for 10 days or conventional therapy alone. A 
total of 97 participants completed six months of follow-up. Th e 
primary outcome was a composite measure of death, dialysis 
dependence, or glomerular fi ltration rate less than 30 ml/min 
per 1.73 m2. At enrollment, dialysis dependence, chemotherapy, 
sex, age, hypercalcemia, serum albumin level, 24-hour urine 
protein level, serum creatinine level, and Durie–Salmon staging 
were similar in the plasma exchange and control groups. Th e 
primary composite endpoint occurred in 33 of 57 (57.9%) 
patients in the plasma exchange group and in 27 of 39 (69.2%) 
patients in the control group (diff erence between groups, 
11.3% (95% CI, –8.3–29.1%); P = 0.36). One-third of patients 
in each group died. Hence, in patients with acute renal failure 
at the onset of multiple myeloma, plasma exchanges did not 
signifi cantly lower the rate of death or dialysis dependence or 
the glomerular fi ltration rate six months later. Limitations of 
the study included its relative small size, use of a composite 
outcome, and lack of renal biopsy as an inclusion criterion. But 
its results suggest no benefi t of plasma exchange. (Ann Intern 
Med 2005; 143: 777–784)
Jai Radhakrishnan
Origin of interstitial fibroblasts in 
a model of angiotensin II-induced 
renal fibrosis
Th e signifi cance of interstitial myofi broblasts and their 
potential generation by epithelial-mesenchymal transition from 
proximal tubular cells is of major interest for our understanding 
of interstitial fi brosis in the progression of renal disease. 
Th e authors of a paper published in the American Journal 
of Pathology examined a model of renal fi brosis in which 
angiotensin is administered aft er acute renal injury. Faulkner et 
al. infused angiotensin II aft er Habu venom injury in rats, then 
examined the origin of interstitial myofi broblasts by locating 
α-smooth muscle actin (α-SMA)-positive and Na+,K+-ATPase-
positive cells relative to interstitial space, tubular epithelial 
cells, the tubular basement membrane (TBM), and vascular 
structures. TBM integrity was also assessed by using Texas Red 
(TR)-dextran in intravital tracking experiments. Th e staining 
of α-SMA-positive myofi broblasts increased in peritubular 
interstitial spaces 48 hours aft er Habu venom plus angiotensin 
II, particularly in and around perivascular and periglomerular 
regions, whereas tubular epithelial cells were α-SMA-negative. 
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Na+,K+-ATPase-positive and TR-dextran-labeled cells were 
restricted to the tubular epithelium and excluded from the 
interstitium. By 7 and 14 days, expanded interstitial space 
contained only α-SMA-positive myofi broblasts without 
TR-dextran endocytic particles. Epithelium of atrophic 
tubules containing TR-dextran remained confi ned by 
surrounding interstitium and myofi broblasts. Th ese studies 
indicate that early expansion of α-SMA-positive cells in the 
interstitium and loss of tubular area occur via encroachment 
of interstitial myofi broblasts from perivascular into atrophic 
tubular spaces rather than via epithelial-mesenchymal 
transition and migration of tubular cells through the TBM 
into the interstitium. Th ese fi ndings cast some doubt on the 
universal validity of the concept of epithelial-mesenchymal 
transition as a major contributor to progressive interstitial 
fi brosis. (Am J Pathol 2005; 167: 1193–1205)
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Neutrophil gelatinase-associated 
lipocalin in acute renal failure
Th ree recent papers support, in a complementary fashion, the 
potential value of neutrophil gelatinase-associated lipocalin 
(NGAL) as a therapeutic for ischemic acute renal failure 
and as an early biomarker for acute renal injury. Mishra 
et al. used a mouse model of renal ischemia-reperfusion 
injury in which they administered purifi ed recombinant 
NGAL. Administration of NGAL in normal mice resulted 
in a rapid uptake of the protein predominantly by proximal 
tubule cells. NGAL administered before, during, or aft er 
renal ischemia markedly improved its morphologic and 
functional (in terms of serum creatinine) consequences. In 
NGAL-treated animals, there was a signifi cant decrease in the 
histopathologic damage to tubules, a reduction in the number 
of apoptotic tubular cells, and an increase in proliferating 
cells. Th ese results indicate that NGAL may represent a novel 
therapeutic intervention in ischemic acute renal failure, 
based in part on its ability to tilt the balance of tubule-cell 
fate toward survival. In a related paper, Mori and colleagues 
studied the renoprotective mechanism of NGAL. NGAL, also 
known as siderocalin, forms a complex with iron-binding 
siderophores (Ngal:siderophore:Fe). Th e authors examined 
the mechanism whereby NGAL:siderophore:Fe protects 
adult kidney epithelial cells or accelerates their recovery from 
damage. In a mouse model of severe acute renal failure, a 
single dose of NGAL (10 µg) introduced during the initial 
phase of the disease dramatically protected the kidney and 
mitigated azotemia.
NGAL activity depends on delivery of the protein and 
its siderophore to the proximal tubule. Iron must also be 
delivered, because blockade of the siderophore with gallium 
inhibits the rescue from ischemia. Th e Ngal:siderophore:Fe 
complex upregulates heme oxygenase-1, a protective enzyme, 
preserves proximal tubule N-cadherin, and inhibits cell 
death. Because mouse urine contains an NGAL-dependent 
siderophore-like activity, endogenous NGAL might also 
play a protective role. Indeed, NGAL accumulates greatly 
in the human kidney cortical tubules and in the blood and 
urine aft er nephrotoxic and ischemic injury. Th us, a novel 
pathway of iron traffi  cking that is activated in renal diseases 
has been detected, providing a new possible therapeutic 
avenue. In a third paper, Mishra et al. demonstrated that 
urinary and serum NGAL concentrations are sensitive and 
specifi c biomarkers of acute renal injury. Th e scarcity of 
early biomarkers for acute renal failure has hindered the 
timely initiation of preventive and therapeutic measures for 
this disorder. Investigators studied 71 children undergoing 
cardiopulmonary bypass. Serial urine and blood samples 
were analyzed by western blotting and enzyme-linked 
immunosorbent assay for NGAL expression. Th e primary 
outcome measure was acute renal injury, defi ned as a 50% 
increase in serum creatinine from baseline. Twenty children 
(28%) developed acute renal injury, but diagnosis with serum 
creatinine was only possible 1–3 days aft er cardiopulmonary 
bypass. By contrast, urine concentrations of NGAL rose from 
a mean of 1.6 µg/l at baseline to 147 µg/l two hours aft er 
cardiopulmonary bypass, and the concentration in serum 
increased from a mean of 3.2 µg/l at baseline to 61 µg/l two 
hours aft er the procedure. Statistical analysis showed that 
NGAL concentrations changes in urine and serum represent 
sensitive, specifi c, and highly predictive early biomarkers for 
acute renal injury aft er cardiac surgery. (J Am Soc Nephrol 
2004; 15: 3073–3082; J Clin Invest 2005; 115: 610–621; Lancet 
2005; 365: 1231–1238)
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